Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has officially changed its legal name from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026. The change was approved by shareholders at the company's annual and special meeting on September 22 and follows the adoption of the Helus Pharma business name in January. This rebranding reflects the company's anticipated transition from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company, a significant milestone for investors and patients alike.
The name change is more than cosmetic. It signals that Helus Pharma is preparing for the next phase of its evolution, moving closer to bringing its innovative treatments to market. The company's common shares will continue trading under the ticker HELP on the Nasdaq Global Market and Cboe Canada, and existing shareholders are not required to take any action. For a company focused on developing proprietary NSAs, this transition underscores its commitment to addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma's pipeline includes HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. These programs highlight the company's potential to improve the treatment landscape with durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland, and is dedicated to helping minds heal through synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.
Investors and stakeholders can stay informed about Helus Pharma's progress through various channels. The latest news and updates relating to HELP are available in the company's newsroom at Helus Pharma. For a deeper look at the company's relationship with MissionIR, visit Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP). To view the full press release, visit https://ibn.fm/rrJFh. More information about the company is available at www.helus.com.
The dissemination of this news is supported by MissionIR, a specialized communications platform. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. These services help companies like Helus Pharma reach a wide audience of investors, influencers, and journalists.
For more information about MissionIR and its services, visit MissionIR. The full terms of use and disclaimers are available at https://www.MissionIR.com/Disclaimer.
